Bone mineral density in patients with Parkinson's Disease

Aging Clinical and Experimental Research

Volumn 20, Issue 3, 2008, Pages 277-279

  Kamanli, Ayhan ^a   Ardicoglu, Ozge ^a   Ozgocmen, Salih ^a   Yoldas, Tahir Kurtulus ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Bone mineral density; Osteoporosis; Parkinson's disease

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; SELEGILINE;

ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HAND; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; OSTEOLYSIS; OSTEOPOROSIS; PARKINSON DISEASE; PHYSICAL DISABILITY; RISK ASSESSMENT; SEX DIFFERENCE; TURKEY (REPUBLIC);

EID: 48449101768     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324774     Document Type: Article

References (18)

1. Aita JF. Why patients with Parkinson's disease fall. JAMA 1982; 247: 515-6.
2. Grisso JA, Kelsey JL, Strom BL, et al. Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Engl J Med 1991; 324: 1326-31.
3. Koller WC, Glatt S, Vetere-Overfield B, Hassanein R. Falls and Parkinson's disease. Clin Neuropharmacol 1989; 12: 98-105.
4. Biering-Sorensen F, Bohr HH, Schaadt OP. Longitudinal study of bone mineral content in the lumbar spine, the forearm and the lower extremities after spinal cord injury. Eur J Clin Invest 1990; 20: 330-5.
5. Chantraine A, Nusgens B, Lapiere CM. Bone remodeling during the development of osteoporosis in paraplegia. Calcif Tissue Int 1986; 38: 323-7.
6. Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1 alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66: 64-8.
7. Ishizaki F, Harada T, Katayama S, Abe H, Nakamura S. Relationship between osteopenia and clinical characteristics of Parkinson's disease. Mov Disord 1993; 8: 507-11.
8. Ishizaki F, Harada T, Katayama S, Abe H, Nakamura S. Bone changes in Parkinson's disease. No To Shinkei 1993; 45: 719-24.
9. Revilla M, de la Sierra G, Aguado F, Varela L, Jimenez-Jimenez FJ, Rico H. Bone mass in Parkinson's disease: a study with three methods. Calcif Tissue Int 1996; 58: 311-5.
10. Di Monaco M, Vallero F, Di Monaco R, Tappero B, Cavanna A. Bone mineral density in hip-fracture patients with Parkinson's disease: a case-control study. Arch Phys Med Rehabil 2006; 87: 1459-62.
11. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients Mov Disord 2005; 20: 1598-603.
12. Ardicoglu O, Ozgocmen S, Kamanli A, Pekkutucu I. Relationship between bone mineral density and radiologic scores of hands in rheumatoid arthritis. J Clin Densitom 2001; 4: 263-9.
13. Kao CH, Chen CC, Wang SJ, Chia LG, Yeh SH. Bone mineral density in patients with Parkinson's disease measured by dual photon absorptiometry. Nucl Med Commun 1994; 15: 173-7.
14. Rico H, Vazquez A, Cabranes JA, et al. Long-term influence of levodopa on bone mass and growth hormone in postmenopausal women with Parkinson's disease. Clin Neuropharmacol 1987; 10: 87-91.
15. Turc JD, Pages M, Paulles JM, et al. Bone changes in Parkinson's disease. Neurology 1993; 43: A236.
16. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci 2001; 182: 89-93.
17. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effects of estrogen replacement on early Parkinson's disease. Neurology 1999; 52: 1417-21.
18. Birdwood G. Normal bone and its development. In: Understanding osteoporosis and its Treatment. New York: Parthenon Publishing, 1996: 17-36.